Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
Lloyd-Jones, Donald M
Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand? [electronic resource] - JAMA cardiology 09 2017 - 937-938 p. digital
Publication Type: Journal Article
2380-6591
10.1001/jamacardio.2017.2288 doi
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents--therapeutic use
Atherosclerosis--blood
Cholesterol, LDL--blood
Drug Therapy, Combination
Ezetimibe--therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use
Hypercholesterolemia--blood
PCSK9 Inhibitors
Patient Selection
RNA, Small Interfering--therapeutic use
Risk Reduction Behavior
Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand? [electronic resource] - JAMA cardiology 09 2017 - 937-938 p. digital
Publication Type: Journal Article
2380-6591
10.1001/jamacardio.2017.2288 doi
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents--therapeutic use
Atherosclerosis--blood
Cholesterol, LDL--blood
Drug Therapy, Combination
Ezetimibe--therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use
Hypercholesterolemia--blood
PCSK9 Inhibitors
Patient Selection
RNA, Small Interfering--therapeutic use
Risk Reduction Behavior